Physician profile
Thomas J Miller
NPI 1407173347
$5,349.47
in general payments reported to CMS, 2019-2025
47 companies · $851 in 2025
The $851 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $352 · 2021: $800 · 2022: $1,090 · 2023: $980 · 2024: $810 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $808.54 | 2021-2025 | |
| Axsome Therapeutics, INC. | $539.96 | 2022-2025 | Auvelity |
| Novo Nordisk INC | $444.03 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $387.67 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $276.70 | 2019-2025 | |
| Amgen INC. | $236.62 | 2020-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.69 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $198.88 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $157.84 | 2019-2022 | |
| Astellas Pharma US INC | $144.75 | 2019-2021 | |
| Glaxosmithkline, LLC. | $138.09 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $133.96 | 2022-2025 | Watchman Flx |
| Dexcom, INC. | $126.44 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $122.14 | 2021-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $114.05 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.